PSH Stock Overview
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Sernova Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.32 |
| 52 Week High | CA$0.78 |
| 52 Week Low | CA$0.26 |
| Beta | 1.48 |
| 1 Month Change | -18.49% |
| 3 Month Change | -21.34% |
| 1 Year Change | -41.16% |
| 3 Year Change | -66.64% |
| 5 Year Change | 139.70% |
| Change since IPO | 137.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| PSH | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -8.2% | -4.3% | -2.5% |
| 1Y | -41.2% | -19.4% | -0.4% |
Return vs Industry: PSH underperformed the German Biotechs industry which returned -19.4% over the past year.
Return vs Market: PSH underperformed the German Market which returned -0.4% over the past year.
Price Volatility
| PSH volatility | |
|---|---|
| PSH Average Weekly Movement | 14.2% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 9.9% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PSH's share price has been volatile over the past 3 months.
Volatility Over Time: PSH's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | n/a | Cynthia Pussinen | www.sernova.com |
Sernova Corp. operates as a clinical-stage regenerative medicine therapeutics company in Canada. The company focuses on the development and commercialization of regenerative medicine therapeutics, including its proprietary Cell Pouch and associated technologies consisting of therapeutic cells and local cellular immune protection. Its Cell Pouch is a novel implantable and scalable medical device which forms a natural environment in the body for the housing and long-term survival and function of therapeutic cells, which release necessary proteins or factors missing from the body to treat chronic diseases as an alternative to daily administration of drugs.
Sernova Corp. Fundamentals Summary
| PSH fundamental statistics | |
|---|---|
| Market cap | €96.27m |
| Earnings (TTM) | -€27.79m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-3.4x
P/E RatioIs PSH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PSH income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$40.73m |
| Earnings | -CA$40.73m |
Last Reported Earnings
Jan 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PSH perform over the long term?
See historical performance and comparison